. N. Effect of SGLT2 inhibitor (Empagliflozin) on HbA1c in most Prevalent Age Group of Type 2 Diabetic Patients. Int J Pathol [Internet]. 2023 Mar. 10 [cited 2025 Dec. 7];20(4):178-81. Available from: https://www.jpathology.com.65-21-161-183.cpanel.site/index.php/OJS/article/view/802